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Abstract
West Nile virus (WNV) has caused multiple global outbreaks with increased frequency of 
neuroinvasive disease in recent years. Despite many years of research, there are no licensed 
therapeutics or vaccines available for human use. One of the major impediments of vaccine 
development against WNV is the potential enhancement of infection by related flaviviruses in 
vaccinated subjects through the mechanism of antibody-dependent enhancement of infection 
(ADE). For instance, the recent finding of enhancement of Zika virus (ZIKV) infection by pre-
exposure to WNV further complicates the development of WNV vaccines. Epidemics of WNV 
and the potential risk of ADE by current vaccine candidates demand the development of effective 
and safe vaccines. We have previously reported that the domain III (DIII) of the WNV envelope 
protein can be readily expressed in Nicotiana benthamiana leaves, purified to homogeneity, and 
promote antigen-specific antibody response in mice. Herein, we further investigated the in vivo 
potency of a plant-made DIII (plant-DIII) in providing protective immunity against WNV 
infection. Furthermore, we examined if vaccination with plant-DIII would enhance the risk of a 
subsequent infection by ZIKV and Dengue virus (DENV). Plant-DIII vaccination evoked antigen-
specific cellular immune responses as well as humoral responses. DIII-specific antibodies were 
neutralizing and the neutralization titers met the threshold correlated with protective immunity by 
vaccines against multiple flaviviruses. Furthermore, passive administration of anti-plant DIII 
mouse serum provided full protection against a lethal challenge of WNV infection in mice. 
Notably, plant DIII-induced antibodies did not enhance ZIKV and DENV infection in Fc gamma 
receptor-expressing cells, addressing the concern of WNV vaccines in inducing cross-reactive 
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antibodies and sensitizing subjects to subsequent infection by heterologous flavivirus. This study 
provides the first report of a WNV subunit vaccine that induces protective immunity, while 
circumventing induction of antibodies with enhancing activity for ZIKV and DENV infection.
Keywords
West Nile virus (WNV); Vaccine; Envelope protein; Domain III (DIII); Antibody-dependent 
enhancement (ADE); Zika virus (ZIKV); Dengue virus (DENV); Plant-produced vaccine; Plant-
made pharmaceuticals
Introduction
West Nile virus (WNV) is a member of the genus Flavivirus in the family Flaviviridae, and 
shares a high degree of sequence similarity to dengue virus (DENV), Zika virus (ZIKV), 
tick-borne encephalitis virus (TBEV), and yellow fever virus (YFV) [1]. For example, WNV 
shares an overall genome structure with these flavivirus and 84%, 66%, 59%, and 52.3% 
nucleotide sequence identity with TBEV, DENV-2, ZIKV, and YFV, respectively [2, 3]. 
WNV entered into the Western hemisphere in the United States (US) in 1999, with cases 
also described in Canada, the Caribbean and Latin American regions [1]. Majority of WNV 
infection in humans is asymptomatic. Symptomatic WNV infection can cause malaise, fever, 
and a maculopapular rash, while neuroinvasive disease symptoms include encephalitis, 
meningitis, and/or possible death [1]. The elderly, individuals who are 
immunocompromised, or those who carry certain genetic factors are at a higher risk of 
developing life-threatening neurological diseases [4, 5]. In recent years, outbreaks of WNV 
have become more frequent and severe with higher instance of patients with neuroinvasive 
complications [6]. However, currently there is no approved WNV vaccine for human use.
One of the challenges for WNV vaccine development is the increased risk of infection by 
related flaviviruses in vaccinated subjects due to the phenomenon of antibody-dependent 
enhancement of infection (ADE). ADE may occur between WNV and related flaviviruses 
such as DENV and ZIKV due to their high degree of genetic similarity and co-circulation in 
many parts of the world [7]. As a result, WNV vaccines based on conserved epitopes among 
related flaviviruses would have the potential to induce cross-reactive antibodies that augment 
entry and replication of DENV and ZIKV in Fc gamma receptor (FcγR)-expressing cells 
and lead to DENV or ZIKV infection in vaccinated subjects [8]. Indeed, mutual 
enhancement between WNV and ZIKV infections has been recently observed [7]. Thus, 
there is an urgent call for the development of WNV vaccines that are not only effective but 
also safe with a minimal risk of ADE to combat the threat of WNV infection on a global 
scale.
WNV Envelope (E) glycoprotein is a major target for the host antibody response and its 
domain III (DIII) contains the majority of type-specific neutralizing epitopes that elicit a 
strong host antibody response and/or protective immunity [9]. For approved human vaccines 
against flaviviruses YFV and TBEV, a neutralizing antibody response has been found to 
correlate with protection [10, 11]. Neutralizing antibodies have also been demonstrated to 
play important roles in the protection against infection by other flaviviruses [12]. As a result, 
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DIII has been explored as a promising WNV vaccine candidate and has been expressed in 
insect and bacterial cell cultures [13, 14]. However, bacterial cell-produced DIII is insoluble 
and demands a solubilization and refolding process to be effective, which is not only 
cumbersome but also inconsistent in producing a recombinant DIII protein with native 
epitopes [14].
In our previous publication, we reported using a plant-based expression system to overcome 
these challenges, for a robust and scalable production of DIII as a promising WNV vaccine 
candidate [15]. We demonstrated that DIII was expressed at high levels in Nicotiana 
benthamiana plants within 4 days post-introduction of the DIII expression cassette. In 
contrast to E. coli-produced DIII, plant-produced DIII (plant-DIII) was soluble, and can be 
readily purified to >95% homogeneity without labor-intensive solubilizing and refolding 
processes [15]. We also demonstrated that immunization of plant-DIII elicited a potent 
antigen-specific antibody response in mice.
Here, we report a follow-up study of the efficacy of plant-DIII as a promising vaccine 
against WNV. In this study, we reveal that plant-DIII can also elicit antigen-specific cellular 
and humoral immune responses, while demonstrating DIII-specific antibodies (anti-plant 
DIII) neutralized WNV with a neutralization titer threshold that correlated with protective 
immunity of other known flavivirus vaccines. Importantly, passive transfer of anti-plant DIII 
serum protected 100% of mice against a lethal WNV challenge. Notably, anti-plant DIII 
antibodies did not enhance infection of ZIKV and DENV in Fc gamma receptor (FcγR)-
expressing cells, offsetting the concern of WNV vaccines in inducing cross-reactive 
antibodies and sensitizing people to subsequent infection by heterologous flaviviruses. In 
brief, our plant-DIII based vaccine can effectively prevent WNV infection, along with 
offering improved safety, and purification efficiency compared to alternative vaccine 
candidates in development.
Material and methods
Ethics statement and biosafety
All animal experimental procedures were reviewed and approved by the Institutional Animal 
Care and Use Committees at The University of Southern Mississippi (USM). All the in vitro 
experiments and animal studies involving live WNV were performed by the certified 
personnel in biosafety level 3 (BSL3) laboratories following standard biosafety protocols 
approved by the USM Institutional Biosafety Committees (IBC). Experiments with ZIKV 
and DENV were conducted with standard biosafety protocols approved by the IBC of 
Arizona State University by the certified personnel in biosafety level 2 (BSL2) laboratories.
Production of WNV envelope protein DIIII in N. benthamiana plants
Plant expression vectors for WNV E DIII [15] was agroinfiltrated into leaves of N. 
benthamiana plants as described previously [16–22]. Leaves were harvested 4 days post 
agroinfiltration (dpi) and DIII was extracted and purified with Ni2+ immobilized metal 
affinity chromatography (IMAC) as previously described [15]. Details of these methods are 
provided in Supplementary material.
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Mouse immunization
Five-week old female BALB/c mice were divided into 2 groups (n = 6 per group). Group 1 
received saline buffer (PBS) with aluminum hydroxide gel (alum, InvivoGen, CA) as mock 
immunized controls and groups 2 received 25 μg of plant-DIII per dosage. On day 0, each 
mouse was injected subcutaneously with 100 μl PBS (Group 1) or 100 μl material containing 
25 μg purified DIII protein (Group 2) in PBS with alum as adjuvant (DIII protein solution: 
alum volume ratio = 1:1). Mice were boosted three times (days 21, 42 and 63 post-
immunization) with the same dosage and immune protocol as in the 1st immunization. 
Retro-orbital blood samples were collected on day 0 before the immunization (pre-immune 
sample) and on days 14 (week 2), 35 (week 5), and 56 (week 8) after the 1st immunization. 
Mice were humanely euthanized on day 77 (week 11), final blood samples were collected, 
and the spleens were aseptically removed for in vitro splenocyte cultures.
In vivo passive antibody transfer protection experiments
Serum isolated from PBS or plant DIII-immunized mice at week 11 was heat-inactivated for 
30 min at 56°C and stored at −80°C. 5-week old female BALB/c mice were divided into 3 
groups (n = 10 per group). Groups 1 and 2 received 50 μl of serum from PBS or plant DIII-
immunized mice, respectively. Group 3 received 10 μg of the monoclonal antibody (mAb) 
E16 [23] as a positive control. Mice anesthetized with 30% isoflurane were passively 
administered serum or E16 mAb via r.o. injection 1 hr before intraperitoneal (i.p.) 
inoculation with 102 plaque-forming units (PFU) of WNV (CT2741, kindly provided by Dr. 
John F. Anderson at the Connecticut Agricultural Experiment Station) in 1% gelatin. Mice 
were monitored for survival for 25 days post infection. The survival curves were constructed 
using data from two independent experiments.
Splenocyte culture and cytokine production
Spleens were isolated and mechanically dissociated to prepare single-cell from immunized 
mice and supernatants from splenocyte cultures were then collected to determine cytokine 
production as described previously [24]. Details of these methods are provided in 
Supplementary material.
Plaque reduction neutralization test (PRNT) assay
WNV-specific neutralizing antibodies were measured with a PRNT assay according to our 
previous report with minor modifications [25–27]. Neutralizing antibody titers were 
expressed as the reciprocal of the highest dilution of serum that neutralized ≥50% of WNV. 
Details of the PRNT method are provided in the Supplementary material.
Antibody-dependent enhancement Assay
Sera collected from vaccinated mice at week 11 were pooled and total IgG was isolated 
using IgG purification kits (GE Healthcare, PA). ADE assay was then performed as 
described previously [25, 28] with details provided in the Supplementary material.
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Statistical analyses
Data analysis was performed using GraphPad Prism software version 6.0 (GraphPad, CA). 
Comparisons of cytokine levels and neutralization potency between groups was performed 
using Mann-Whitney test. Comparison of concentrations of cytokines collected at various 
time points was performed by one-way ANOVA. Survival data from at least two independent 
experiments (n = 10) were analyzed by a Kaplan-Meier analysis. A p value of < 0.05 
indicated statistically significant difference.
Results
Plant-DIII elicited antigen-specific cellular immune responses
BALB/c mice were injected subcutaneously with four doses of plant-DIII with alum as an 
adjuvant over an 11-week time period (Fig S1). Mice in group 1 received PBS as a negative 
control and mice in group 2 received 25 μg of plant-DIII. Retro-orbital blood collection from 
mice was performed on day 0 before the immunization (pre-immune sample), day 14 (week 
2), day 35 (week 5), and day 56 (week 8) after the initial dose immunization. On week 11, 
all mice were euthanized and the spleens were aseptically removed for in vitro splenocyte 
cultures. Our previous report showed that plant-DIII induced significant titers of antigen-
specific IgG (log titers > 3.6 and 4.3 for week 5 and 8, respectively), while no significant 
DIII-specific IgG titer was detected in sera collected from PBS-injected mice [15]. We have 
also previously reported that the antibody response generated by plant-DIII, with alum as the 
adjuvant, included both IgG1 and IgG2 subtypes with higher concentrations of IgG1 
detected than IgG2a [15].
To determine if plant-DIII induced an antigen-specific cellular immune response in mice, the 
production of cytokines by splenocytes from immunized mice was measured after in vitro 
antigen stimulation for 24 and 48 hr. As expected, splenocytes of mice in the group that 
received PBS did not produce significant titers of cytokines after in vitro stimulation with 
plant-DIII (Fig 1A). In contrast, splenocytes from plant DIII-inoculated mice secreted 
significant levels of IL-4 (Fig 1B), IL-6 (Fig 1C), and IFN-γ (Fig 1D). The mean 
concentrations of IL-6 and IL-4 are higher than that of IFN-γ after both 24 and 48 hr 
stimulation (p = 0.0009 and 0.0008 for 24 hr and 48 hr samples, respectively). In addition, 
the competency of splenocytes in producing cytokines was demonstrated by the detection of 
high levels of IFN-γ upon stimulation with the positive control, ConA (Fig S2). These 
results demonstrated that plant-DIII evoked both Th1 and Th2-type antigen-specific cellular 
immune responses.
Serum from plant-DIII immunized mice exhibited potent neutralizing activities against WNV
The ability of induced antibodies in response to plant DIII immunization to confer 
neutralization against WNV was examined by a PRNT assay with serum samples collected 2 
weeks after the 2nd immunization (week 5 serum). No significant reduction of WNV 
infection was detected for sera from mice injected with PBS (Fig 2). In contrast, sera from 
mice that received plant-DIII vaccination exhibited potent neutralizing activities against 
WNV infection as early as week 5 (p <0.005 comparing anti-plant DIII sera versus PBS 
sera) (Fig 2). Specifically, greater than 44% and 70% of WNV infection was reduced by sera 
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from plant DIII-vaccinated mice that have been diluted by 100 and 10 folds, respectively 
(Fig 2). Neutralization titers that correlate with protection in humans and animal models 
have been established for several flaviviruses including YFV, TBEV, and lately ZIKV [29–
32]. These studies revealed that antibody responses with neutralization titers >10 are 
sufficient to provide protective immunity against these viral infections [29–32]. Our results 
indicate that plant-DIII also induced a neutralization titer that is > 10, meeting the 
established protective threshold.
Plant-DIII induced protective immunity that protects mice against lethal WNV infection
Although the PRNT results suggested the protective nature of plant-DIII evoked immune 
responses, it was essential to demonstrate this activity in vivo. Challenge studies were 
performed in 5-week-old wild-type BALB/c mice (n = 10 per group) to examine if sera from 
plant DIII-vaccinated mice protected against WNV infection in recipient mice. Mice were 
first passively administered pooled heat-inactivated sera collected at week 11 from plant 
DIII-inoculated or PBS-injected mice (negative control) via an r.o. route and then infected 
with 102 PFU of WNV, which causes a baseline mortality of 80–90% [23]. A protective E16 
mAb [23] was also r.o. injected in parallel as a positive control. Indeed, 80% of mice in the 
negative control group that received PBS-injected serum succumbed to infection and died 
within 10 days of WNV inoculation (Fig 3). In contrast, 80% of mice that received the 
positive control E16 mAb were protected (Fig 3). Notably, 100% of mice receiving plant 
DIII-vaccinated serum (with anti-DIII log titer > 4.4 and neutralization titer >10) were 
completely protected from the lethal infection (p < 0.0001) (Fig 3). These results indicate 
that plant-DIII elicited an antibody response that can protect mice against WNV infection.
Antibody-dependent enhancement activities of IgGs from plant DIII-vaccinated mice
One of the major challenges of vaccine development for WNV and other flaviviruses is the 
risk of ADE of heterologous flavivirus (e.g. ZIKV and DENV) infection. As such, we 
investigated if plant-DIII vaccine would induce antibodies that enhance the infection of 
ZIKV or DENV. As previously demonstrated [33], 4G2, an anti-DENV E mAb that cross-
reacts with E of other flaviviruses, efficiently caused ADE of ZIKV (Fig 4A) and DENV-2 
(Fig 4C) infection in K562 cells that express the human FcγR. In contrast, IgGs from the 
negative control mice (week 11) that received PBS did not promote ADE for ZIKV (Fig 4B) 
or DENV-2 (Fig 4D). Likewise, IgGs from plant-DIII vaccinated mice displayed no 
significant ADE activity for ZIKV (Fig 4B) or DENV-2 (Fig 4D). PRNT analysis revealed 
that high concentrations of plant-DIII evoked IgGs used in the ADE assay have neutralizing 
activity (data not shown), confirming the lack of ADE is not due to insufficient amount anti-
DIII IgGs in the assay.
Discussion
The continuous global outbreaks of WNV and its clinical effects on the central nervous 
system and long-term morbidity call for the development of vaccines especially in the 
absence of an effective treatment. Current WNV vaccine candidates include inactivated 
WNV, live-chimeric virus based on canarypox virus or YFV, DNA-based vaccines, and 
protein subunit vaccines based on the WNV E protein [34–36]. Studies with these candidates 
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demonstrated that neutralizing antibody responses are essential in providing protection 
against WNV infection [34–37]. Among these vaccine candidates, the protein subunit-based 
vaccines with WNV E are projected to be the safest due to lack of risks associated with 
incomplete inactivation of a live virus, unfavorable host responses to viral vectors, and 
oncogenesis due to the potential insertion of DNA vaccine fragment into the host genome. 
However, attempts to produce a WNV E protein or its sub-domains in traditional expression 
systems such as E. coli or insect cell cultures are challenged by several obstacles including 
purification and epitope preservation [14, 38]. Safety concerns of WNV vaccines in 
worsening symptoms of secondary ZIKV and DENV infections via ADE further ignite an 
urgent need for safer WNV vaccines.
Neutralizing antibody responses with neutralization titers > 10 against E protein has been 
found to correlate with protection of various flavivirus vaccines and vaccine candidates 
including those against YFV, TBEV, ZIKV, and WNV [10, 11, 29–32]. We have shown that 
some anti-plant DIII antibodies compete with a known protective mouse antibody [15, 39–
41], suggesting potentially protective antibodies can be produced by plant-DIII 
immunization. Consistent with this hypothesis, our current study demonstrated that anti-
plant DIII antibodies have potent neutralizing activities that meets an established threshold 
(neutralization titer >10) required for protective immunity by various flavivirus vaccines in a 
mouse model. This was later confirmed by our in vivo study in which 100% of mice that 
received mouse plant-DIII sera were protected from a lethal challenge of WNV infection (p 
< 0.0001 compared to mice receiving PBS-injected mouse sera). Collectively, these results 
demonstrated that plant-DIII can elicit a neutralizing antibody response that provides 
protective immunity against WNV infection.
Our current study also demonstrated that plant-DIII also evoked antigen-specific cellular 
immune responses. Consistent with our previous finding that plant-DIII elicited both IgG1 
and IgG2a responses [15], our cytokine profiling also indicated the induction of both Th1 
and Th2-type cytokines with mean concentrations of Th-2 type cytokines higher than that of 
the Th1-type. This is not totally unexpected as comparative studies with flavivirus antigens 
showed that the adjuvant alum tends to skew the response toward the Th2-type [42, 43]. In 
this study, alum was used as the adjuvant because it has been successfully employed in 
licensed human vaccines against other flaviviruses [44]. While a Th1-type response is 
generally more preferable than a Th2-type for preventing and treating viral infection, studies 
have shown that a Th1/Th2 mixed response, one that was induced by plant-DIII with alum, 
can be just effective [45]. The background levels of IL-6 observed secreted by splenocytes of 
PBS-injected mice were higher than that of the other cytokines. Further experiment is 
required to investigate the reasons behind this observation. The induction of both humoral 
and cellular responses by plant-DIII indicates its potential in clearing WNV infection, as 
well as in providing sterilizing immunity against subsequent WNV challenge.
Vaccine development for some flaviviruses, such as DENV, has been impeded by the issue 
of ADE. For example, previous infection or vaccination against one serotype of DENV may 
predispose these individuals to develop the more severe dengue hemorrhagic fever/dengue 
shock syndrome (DHF/DSS) through ADE if they are exposed to another serotype of DENV 
subsequently [46]. The recent outbreaks of ZIKV further complicate vaccine development 
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for flaviviruses as antibodies against DENV, WNV, and ZIKV have been shown to cross-
react and enhance the replication of each other both in cell culture and in mice infection 
studies, suggesting ADE can occur between these related viruses, which are co-circulating in 
many parts of the world [7, 47–49]. Therefore, minimizing ADE with heterologous 
flavivirus infection must be an important consideration for WNV vaccine development.
Structural studies have indicated that domain I and II (DI and DII) of the E protein are 
highly conserved among flaviviruses [50]. Likewise, the majority of flavivirus cross-reactive 
but subneutralizing antibodies in human humoral response to flavivirus E protein are 
targeted to epitopes on DII or DI [49, 51, 52]. In contrast, antibodies against DIII epitopes 
are overall virus-specific, have potent neutralizing activity, and many are protective against 
flavivirus challenge in mice [12, 49, 53]. For example, antibodies against ZIKV DIII did not 
enhance DENV infection, while ZIKV DI and DII-specific antibodies exhibited strong ADE 
activity both in vitro and in vivo [49]. Of note, our results provided direct evidence that 
antibodies induced by plant-DIII did not enhance ZIKA or DENV infection in vitro, 
warranting further testing in animal models. In contrast, all other current WNV vaccine 
candidates based on inactivated, chimeric virus, or DNA, have the potential to elicit DI/DII-
cross reactive, subneutralizing antibodies that can enhance ZIKV or/and DENV infection in 
vaccinated subjects. Therefore, our plant-DIII based vaccine may have a safety advantage 
over the current WNV vaccine candidates in development.
In summary, we have demonstrated potent efficacy of a plant-produced DIII vaccine that 
protects against WNV infection both in vitro and in vivo. More importantly, we also further 
demonstrated the lack of ADE activity for ZIKV and DENV infection in vitro with our 
plant-DIII vaccine candidate. To our knowledge, this is the first report of a WNV subunit 
vaccine that induces protective immunity, while circumventing the induction of cross-
reactive antibodies that may enhance ZIKV and DENV infection via ADE. Altogether, our 
study has provided a proof-of-principle for further development of an effective and 
potentially safer recombinant protein-based subunit vaccine against WNV infection.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Splenocyte cytokine production from plant-DIII immunized mice
Spleen cells from mice injected with PBS (A) or 25 μg plant-DIII (B–D) were stimulated in 
vitro with DIII for 24 to 48 hr. The production of IL-4 (A and B), IL-6 (A and C), and IFN-
γ (A and D) was quantitated by a multiplex mouse cytokine kit. Mean concentration (pg/ml) 
and standard deviation (SD) from at least two independent experiments with technical 
triplicates for each sample are presented. Compared with unstimulated samples, significant 
induction of cytokines by antigen stimulation are observed (p = 0.002 for IL-4 and IL6 both 
24hr and 48 hr; and p =0.002 for IFN-γ 48 hr). Significant difference in cytokine levels are 
also observed between splenocytes from plant-DIII vaccinated mice and control mice 
receiving PBS (p = 0.002 for IL-4 and IL-6 both 24hr and 48 hr; and p < 0.002 for IFN-γ 48 
hr).
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Figure 2. Neutralization of WNV by anti-plant DIII serum
Pooled sera from week 5 of vaccinated mice receiving PBS or plant-DIII were diluted 10 
and 100 folds, respectively and incubated with 102 PFU of WNV prior to infection in Vero 
cells. WNV-specific neutralizing antibodies in the sera were assessed with a PRNT assay. 
PBS buffer was used as the negative control (− Control) in the PRNT assay. Mean % 
neutralization and SD from two independent experiments with technical triplicates for each 
sample are presented. ** indicates p values < 0.005 of DIII-immunized serum compared to 
that from PBS-inoculated control mice.
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Figure 3. Mice protected from WNV infection by passive administration of serum collected from 
plant-DIII immunized mice
Serum was collected from mice that were immunized with plant-DIII (Plant DIII) or PBS. 
After heat-inactivation, BALB/c mice were passively administered (r.o.) 50 μl of serum or 
10 μg of E16 mAb (Positive Control) before infection with 102 PFU of WNV. The p-value is 
indicated for the plant DIII curve. Data reflect two independent experiments with n = 10 
mice per treatment.
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Figure 4. Lack of enhancement of ZIKV and DENV infection by antibodies in anti-plant DIII 
serum
Serum collected at week 11 from PBS or plant-DIII vaccinated mice were pooled and IgGs 
were isolated from the pool sera. Serial dilutions of IgGs were mixed with ZIKV (A and B) 
or DENV-2 (C and D) and incubated with FcγR expressing K562 cells. After 48 hr of 
incubation, cells were fixed, permeabilized and analyzed by flow cytometry for viral 
infection. Anti-flavivirus E mAb 4G2 was used as an ADE positive control (A and C). 
Enhancement by IgGs from sera is expressed as a % relative to that of 4G2 (B and D).
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